Common sleep drugs may foil brain’s waste-clearance process
HQ Team January 17, 2025: The commonly prescribed sleep medications, particularly zolpidem, known by its brand name Ambien, may disrupt the brain’s natural
Health
Medical
Research
Health
Medical
Hormonal contraceptives and breast cancer risk in BRCA1 carriers
HQ Team January 17, 2025: A study has found a significant association between the use of hormonal contraceptives and an increased risk of
Drugs
Health
Pharma
US drug regulator rejects Atara Biotherapeutics’ rare cancer therapy
Atara Biotherapeutics’ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug
Drugs
Health
Medical
Eli Lilly’s Omvoh gains FDA approval for treating Crohn’s disease
HQ Team The US Food and Drug Administration (FDA) has approved Eli Lilly’s Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active
Health
Pharma
Research
Beyond body mass index, experts hone in on new definition of obesity
Obesity, as defined by the standard body mass index, is erroneous, and the condition should be split into two — pre-clinical and clinical,
Health
Medical
Pharma
Eight people die in Tanzania due to possible Marburg virus disease: WHO
At least eight people have died in Tanzania of suspected Marburg Virus Disease (MVD) and the regional risk is “high,” according to a
Drugs
Medical
Research
India’s Tata Group grants $57.8 million to build medical school in IT capital
Tata Group, a $165 billion Indian conglomerate, is set to build a medical school in the southern technology hub of Bengaluru by partnering
Drugs
Health
Pharma
Daiichi Sankyo to buy cancer antibody from Glycotope for $132.5 million
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from
Drugs
Health
Medical
Eli Lilly to buy Scorpion Therapeutics’ cancer drug for $2.5 billion
Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid
Drugs
Medical
Pharma
Johnson & Johnson to acquire Intra-Cellular Therapies Inc., for $14.6 billion
Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to